The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. The stock was recently discussed on Yahoo Finance as it revealed that Biogen to Realign Resources for Alzheimer’s Disease Franchise.
Biogen Inc is listed on the NASDAQ as a member of the Healthcare sector and is a part of the Drug Manufacturers – General industry. At the end of the last regular session, the stock closed at $247.83 and fluctuated between $249.33 as its day high and $240.00 as its day low. The current market capitalization of Biogen Inc is $35.91B. A total of 0.92 million shares were traded on the day, compared to an average of 1.09M shares.
Additionally, investors take into account insider trades when predicting how a stock will perform. During the recent three months, BIIB has seen 0 BUY and 0 SELL insider trades, representing the acquisition of 0 and the disposition of 0 shares. Over the last 12 months, there were 34 BUYs and 38 SELLs from insiders. Insiders purchased 41,812 shares during that period but sold 25,070.
In the most recent transaction, Singhal Priya sold 110 shares of BIIB for 248.00 per share on Dec 11. After the transaction, the Head of Development now owns 3,464 company shares. In a previous transaction on Sep 26, BIOGEN INC. sold 6,000,000 shares at 0.50 per share. BIIB shares that 10% Owner owns now total 17,652,466.
Among the insiders who sold shares, Singhal Priya disposed of 431 shares on Sep 05 at a per-share price of $269.43. This resulted in the Head of Development holding 3,354 shares of BIIB after the transaction. In another insider transaction, Singhal Priya sold 81 shares at $282.87 per share on Jul 03. Company shares held by the Head of Development now total 2,924.
Though price targets are rarely accurate, they can exert some influence from time to time and were often accepted as valuable by the market. According to analysts who have offered 12-month price targets for BIIB in the last 3 months, the mean price target is $315.07 with high estimates of $406.00 and low estimates of $245.00. In terms of 52-week highs and lows, BIIB has a high of $319.76 and a low of $220.86.
As of this writing, BIIB has an earnings estimate of $Biogen Inc. per share for the current quarter. EPS was calculated based on a consensus of Bitwise Bitcoin ETF Common Shar estimates, with a high estimate of $Roundhill BIG Bank ETF per share and a lower estimate of $Bitwise Bitcoin ETF.
Balance Sheet Annually/Quarterly
A balance sheet is a report that shows the company’s assets and liabilities. In addition, it shows how much equity investors have invested in the company. Investors can determine the company’s prospects by calculating its financial ratios based on this information. BIIB’s latest balance sheet shows that the firm has $3.80B in Cash & Short Term Investments as of fiscal 2021. There were $7.60B in debt and $4.30B in liabilities at the time. Its Book Value Per Share was $99.96, while its Total Shareholder’s Equity was $10.96B.
It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for BIIB is Buy with a score of 4.39.